NEW YORK, August 25, 2017 /PRNewswire/ --
If you want a Stock Review on GILD, BIIB, BLUE, or BMRN then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. DailyStockTracker.com covers the Biotech industry, which focuses on novel drug development and clinical research aimed at treating diseases and medical conditions. Companies in this space are almost always unprofitable, and many have no real revenue at all. Equities to be assessed this morning are: Gilead Sciences Inc. (NASDAQ: GILD), Biogen Inc. (NASDAQ: BIIB), bluebird bio Inc. (NASDAQ: BLUE), and BioMarin Pharmaceutical Inc. (NASDAQ: BMRN). Access DailyStockTracker.com's complimentary reports for today's stocks line-up at:
Shares in Foster City, California headquartered Gilead Sciences Inc. rose 0.38%, ending Thursday's trading session at $74.02. The stock recorded a trading volume of 4.91 million shares. The Company's shares have gained 14.65% over the last three months and 3.37% on an YTD basis. The stock is trading 3.43% and 5.24% above its 50-day and 200-day moving averages, respectively. Moreover, shares of Gilead Sciences, which discovers, develops, and commercializes medicines in the areas of unmet medical needs in Europe, North America, Asia, South America, Africa, Australia, India, and Middle-East, have a Relative Strength Index (RSI) of 56.62.
On July 26th, 2017, Gilead Sciences announced that its Board of Directors has declared a cash dividend of $0.52 per share of common stock for the third quarter of 2017. The dividend is payable on September 28th, 2017, to stockholders of record at the close of business on September 15th, 2017. Future dividends will be subject to Board's approval. Visit us today and access your complete report on GILD for free at:
Cambridge, Massachusetts headquartered Biogen Inc.'s stock climbed 0.99%, closing the day at $285.45 with a total trading volume of 792,419 shares. The Company's shares have advanced 12.84% in the previous three months and 9.28% since the start of this year. The stock is trading 2.06% and 4.46% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Biogen, which discovers, develops, manufactures, and delivers therapies for the treatment of neurological and autoimmune diseases worldwide, have an RSI of 51.41.
On July 26th, 2017, research firm Goldman upgraded the Company's stock rating from 'Neutral' to 'Buy'.
On July 31st, 2017, Biogen announced the appointment of Anabella Villalobos, Ph.D. as Senior Vice President, Biotherapeutic & Medicinal Sciences (BTMS). Dr. Villalobos will lead the Company's BTMS organization in the delivery of high-quality, differentiated molecules to the clinic. She will report to Michael Ehlers, M.D., Ph.D., Executive Vice President, Head of R&D. The complimentary research report on BIIB can be accessed at:
On Thursday, shares in Cambridge, Massachusetts headquartered bluebird bio Inc. recorded a trading volume of 377,739 shares. The stock ended the day 2.87% higher at $98.60. The Company's shares have surged 23.56% in the previous three months and 59.81% on an YTD basis. The stock is trading above its 200-day moving average by 17.83%. Furthermore, shares of bluebird bio, which focuses on developing transformative gene therapies for severe genetic diseases and cancer, have an RSI of 53.56.
On August 02nd, 2017, bluebird bio reported financial results for Q2 ended June 30th, 2017. For Q2 2017, total revenue was $16.7 million; R&D expenses were $64.3 million; G&A expenses were $21.2 million; and net loss was $70.9 million. Cash, cash equivalents, and marketable securities as of June 30th, 2017, were $1.2 billion.
On August 17th, 2017, research firm Evercore ISI initiated an 'In-line' rating on the Company's stock, with a target price of $102 per share. Register for free on DailyStockTracker.com and download the research report on BLUE at:
San Rafael, California headquartered BioMarin Pharmaceutical Inc.'s stock gained 1.29%, finishing yesterday's session at $82.45 with a total trading volume of 775,193 shares. The Company's shares are trading below their 50-day moving average by 6.74%. Shares of the Company, which develops and commercializes pharmaceuticals for serious diseases and medical conditions in the US, Europe, Latin America, and internationally, have an RSI of 40.45.
On August 17th, 2017, research firm Evercore ISI initiated an 'Outperform' rating on the Company's stock, with a target price of $100 per share.
On August 21st, 2017, BioMarin Pharma announced that it has been ranked 12th on Forbes' 2017 list of the "World's Most Innovative Companies." This is the fourth consecutive year that the Company has received the recognition, acknowledging its commitment to making an impact in the lives of small patient populations. The two previous years, the Company was ranked 10th, and in 2014, it ranked 7th. Get free access to your research report on BMRN at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number: (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.